Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegbelfermin
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegbelfermin is a polyethylene glycol-conjugated recombinant analog of human fibroblast growth factor 21 (FGF21), designed to have an extended half-life for weekly dosing. It acts as an agonist/mimetic of FGF21, a non-mitogenic hormone that regulates glucose and lipid metabolism and plays a critical role in energy homeostasis. Pegbelfermin is under investigation primarily for the treatment of nonalcoholic steatohepatitis (NASH), where it has shown efficacy in reducing hepatic steatosis, improving fibrosis biomarkers, and modulating metabolic parameters in clinical trials. The drug also reduces secondary bile acid concentrations and impacts the gut microbiome. Developed by Bristol Myers Squibb, pegbelfermin represents a novel approach targeting metabolic dysfunctions associated with NASH[1][2][3][4][5][6][8].
- Other names
- PGBFpolyethylene glycol-modified FGF21 analog
02
Targets
FGFR-KLB complex (Fibroblast growth factor receptor 1c / beta-Klotho complex)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on pegbelfermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegbelfermin.